Humacyte (NASDAQ:HUMA) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report report published on Monday morning,Benzinga reports. They currently have a $25.00 target price on the stock.

Several other brokerages also recently issued reports on HUMA. UBS Group reaffirmed a “buy” rating on shares of Humacyte in a research report on Monday, December 1st. Wall Street Zen downgraded Humacyte from a “hold” rating to a “sell” rating in a research note on Sunday. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Humacyte in a report on Monday, December 1st. Barclays initiated coverage on Humacyte in a report on Wednesday, August 27th. They set an “overweight” rating and a $3.50 price target for the company. Finally, BTIG Research reissued a “buy” rating and issued a $6.00 price objective on shares of Humacyte in a research report on Friday, November 21st. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Humacyte currently has an average rating of “Moderate Buy” and a consensus price target of $8.29.

Humacyte Trading Down 3.6%

NASDAQ:HUMA opened at $1.07 on Monday. The company’s 50 day moving average is $1.39 and its 200-day moving average is $1.79. The company has a quick ratio of 0.90, a current ratio of 1.62 and a debt-to-equity ratio of 2.97. Humacyte has a 12 month low of $1.06 and a 12 month high of $5.66. The firm has a market cap of $200.38 million, a price-to-earnings ratio of -4.65 and a beta of 1.90.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.03. The firm had revenue of $0.75 million for the quarter, compared to the consensus estimate of $0.92 million. Equities analysts anticipate that Humacyte will post -1.27 EPS for the current year.

Institutional Trading of Humacyte

Several institutional investors have recently modified their holdings of the company. Lazari Capital Management Inc. bought a new stake in shares of Humacyte during the second quarter valued at approximately $27,000. Truist Financial Corp bought a new position in Humacyte in the third quarter worth $28,000. Prudential Financial Inc. acquired a new stake in Humacyte during the second quarter worth $28,000. Financial Advisors Network Inc. acquired a new stake in Humacyte during the second quarter worth $28,000. Finally, Equitable Holdings Inc. bought a new stake in Humacyte in the 3rd quarter valued at $29,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.